Trial Profile

An Exploratory Study of αPD1-MSLN-CAR T Cells Secreting PD-1 Nanobodies for the Treatment of MSLN-positive Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 31 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BZDS 1901 (Primary)
Indications Cholangiocarcinoma; Colorectal cancer; Ovarian cancer; Solid tumours
Focus Adverse reactions

Most Recent Events

24 Oct 2022 Planned End Date changed from 1 Sep 2022 to 1 Aug 2023.
24 Oct 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Feb 2023.
17 May 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com